July 26, 2021
Phase 3 Randomized Double-Blind Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma
TYPE OF SARCOMA: Advanced Dedifferentiated Liposarcoma
DRUG: Abemaciclib
ACCRUAL STATUS: Recruiting
OVERALL STUDY PRINCIPAL INVESTIGATORS:
Mark Dickson, MD
Memorial Sloan Kettering Cancer Center
CLINICALTRIALS.GOV IDENTIFIER: NCT04967521
FOR STUDY DETAILS AND ELIGIBILITY CRITERIA: CLINICALTRIALS.GOV
To learn more about this study view Dr. Dickson’s SARC041 presentation at the 2021 SARC Semiannual Meeting:
To contact the study research staff: